Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Teva Neuroscience, Inc.
With
H. Lundbeck A/S
Age
30–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
receiving stable dose of oral ropinirole or pramipexole whose symptoms are not optimally controlled or whose oral dopamine agonist titration regimen was truncated due to intolerability:
1\) Minimum dose of agonist will be 6 mg/day for ropinirole and 1.0 mg/day for pramipexole
2\) Stable dopamine agonist treatment must have been ongoing for ≥ 30 days, no longer than 5 years preceding baseline
Males and females. Women of childbearing potential must agree to practice an acceptable method of birth control.
Idiopathic Parkinson Disease confirmed at baseline by presence of at least 2 cardinal signs (resting tremor, bradykinesia, rigidity), w/o other known or suspected cause of Parkinsonism
Hoehn \& Yahr \> 1 (symptoms on only one side of the body) with treatment and \< 3 (mild to moderate bilateral disease; some postural instability; physically independent).
Dopamine agonist dose must be stable for ≥30 days preceding the baseline visit.
For patients who are receiving amantadine or anticholinergics, the dose must have been stable for ≥30 days prior to screening.
